This website uses technical, customisation and analytical cookies, both first-party and third-party, to anonymously facilitate browsing and analyse statistics on use of the website. Learn more
Darden University of Virginia (USA)
-
A Game Too Far
Parmar, Bidhan L.; Gregorio, Alex; Mead, JennyCase DARDEN-E-0465Business Ethics and Corporate Social ResponsibilityThe protagonist in this case, founder of a successful, privately held tabletop board gaming company, has to make some tough decisions about whether to move forward with two of the company's board games. Recent years had seen a renaissance for board games and their audience, and the board game market, driven primarily by millennials, was estimated to be worth roughly $12 billion dollars by 2023. The decision is whether to print a second run of T...Starting at €8.20
-
A Game Too Far
Parmar, Bidhan L.; Gregorio, Alex; Mead, JennyCase DARDEN-E-0465-EBusiness Ethics and Corporate Social ResponsibilityThe protagonist in this case, founder of a successful, privately held tabletop board gaming company, has to make some tough decisions about whether to move forward with two of the company's board games. Recent years had seen a renaissance for board games and their audience, and the board game market, driven primarily by millennials, was estimated to be worth roughly $12 billion dollars by 2023. The decision is whether to print a second run of T...Starting at €8.20
-
The Sanofi-Aventis Acquisition of Genzyme: Contingent Value Rights
Matos, Pedro; Aleyev, Dmitriy; Xu, ChongCase DARDEN-F-1715-EFinanceThis case is designed for MBA students in M&A or derivatives courses. In January 2011, Sanofi-Aventis was finalizing its offer terms for acquiring Genzyme. The M&A valuation disputes were about the market potential of alemtuzumab, a drug in Genzyme’s pipeline, and how quickly Genzyme could resolve some of its manufacturing issues. To bridge the gap in their estimates, advisers had suggested an up-front cash payment and a contingent value right (C...Starting at €8.20
-
Sanofi-Aventis's Tender Offer for Genzyme
Eades, Kenneth M.; Matos, Pedro; Aleyev, Dmitriy; Xu, ChongCase DARDEN-F-1716-EFinanceIn October 2010, Henri Termeer, the chairman and CEO of Genzyme, received a letter from the CEO of Sanofi-Aventis announcing its intention to commence a tender offer for Genzyme. Termeer thought the offer undervalued Genzyme, given the number of promising new drugs in the company’s pipeline and the success of its current drug portfolio. The case focuses on the strategic and financial considerations of a large corporate acquisition. To estimate Ge...Starting at €8.20